Cover Image
市場調查報告書

下一代血糖控製藥

Next-Generation Glycemic Control Therapeutics

出版商 Greystone Research Associates 商品編碼 337816
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
下一代血糖控製藥 Next-Generation Glycemic Control Therapeutics
出版日期: 2015年08月24日 內容資訊: 英文
簡介

在糖尿病患者數於全球持續增加之下,藥物開發商及研究人員摸索著適合,尤其是第二型用的控制血糖值的更有效方法。透過這些配合措施,已透過核准或後期開發階段的GLP-1受體激動劑及DPP-4抑制劑的清單擴充,以及新醫藥成分的藥物和有獨有的潛在優點的藥物聚集關心,成為研究的投資對象。

本報告提供下一代血糖控製藥的市場相關調查、已透過核准藥物種類與概要、已透過核准藥物的全球市場規模、投藥及處方相關趨勢與課題、開發後期階段的產品種類與概要、相關法律與其課題、影響市場成長因素分析、競爭環境、主要經營者簡介等彙整資料。

摘要整理

市場機會

  • 血糖控制市場力學
  • 市場區隔
  • 市場促進因素
  • 人口組成的變化
  • 藥物需求的推進因素
  • 競爭環境
  • 風險因素

已透過核准下一代治療藥

  • 吸入型胰島素
  • GLP-1受體激動劑
  • Amylin Analogs
  • DPP-4抑制劑
  • 鈉葡萄糖共轉運體2 (SGLT2) 抑制劑

開發階段的血糖控制產品

  • 胰島素
  • 吸入型胰島素
  • GLP-1受體激動劑
  • DPP-4抑制劑
  • SGLT2抑制劑
  • 2劑並用藥
  • 新的MOA
    • PPAR
    • 升糖素受體拮抗劑

市場資料、預測

市場影響因素

  • 法律規章上的課題
  • 患者的服藥遵守、是否容易使用
  • 醫療經濟學
  • 地區性的市場影響因素

企業簡介

目錄
Product Code: GCT494R

The Promise of New Drug Classes & MOAs

As the number of patients diagnosed with diabetes continues to climb worldwide, drug developers and researchers are attempting for find more effective ways to control glucose levels, particularly for Type 2 diabetics. These efforts have led to a growing list of GLP-1 agonists and DPP-4 inhibitors that have been approved or are in late stage clinical development. New medicines based on novel therapeutic moieties and potentially unique benefits are attracting attention and research investment. The result is an evolving therapeutic landscape that is providing clinicians and patients with new ways to manage their diabetes. For market participants, product positioning and prescriber training will become increasingly important as competitive threats remain fluid.

The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.

Market-driven Product Strategies

A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.

The market for glycemic control continues to grow globally at rates that are alarming to public health officials. Over the past decade, prevalence of diabetes among adults has increased by 33 percent. In the United States, approximately 6 percent of the population (i.e., 16 million people) has diabetes and it is the fourth-leading cause of death by disease. Among Americans in their thirties, diabetes has increased by 70 percent in the past 10 years. Each year, approximately 798,000 people are diagnosed with diabetes. However, one-third of the people afflicted are currently undiagnosed.

Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.

What You Will Learn

  • What therapeutic drugs are currently marketed for glycemic control, how are they administered, who markets them, and what is the size of the global market?
  • What are the important factors in patient self-administration of glycemic drugs, what are the current prescribing trends, and what are the key factors influencing demand?
  • What are the regional factors affecting market size and demand?
  • What are the new classes of drugs that are entering the market for treating diabetes, what is their market share and what are their growth prospects?
  • What drugs are expected to enter the market in the next five years, and what will be their probable impact on the overall market?
  • What are the significant economic, technology, and regulatory factors affecting the market for glycemic control therapeutics?

Table of Contents

  • Executive SummaryThe Market Opportunity
  • Glycemic Control Market Dynamics
  • Market Segments
  • What's Driving the Market?
  • Shifting Demographics
  • Therapeutic Demand Drivers
  • Competitive Landscape
  • Risk Factors
  • Approved Next-Generation Therapeutics
  • Inhaled Insulin
  • GLP-1 Agonists
  • Amylin Analogs
  • DPP-4 Inhibitors
  • Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors
  • Development-stage Glycemic Control Products
  • Insulins
  • Inhaled Insulin
  • GLP-1 Agonists
  • DPP-4 Inhibitors
  • SGLT2 Inhibitors
  • Dual Therapy Drugs
  • New MOAs
  • PPARs
  • Glucagon Receptor Antagonist
  • Market Data and Forecasts
  • Market Factors
  • Regulatory Issues
  • Patient Compliance and Ease of Use
  • Healthcare Economics
  • Regional Market Factors
  • Company Profiles
Back to Top